• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
5N Plus Inc
Ainos, Inc. - Common Stock
Atwec Technologies Inc
Bactech Environmental Crp
Blue Gold Limited - Warrant
Cvent Holding Corp. - Common Stock
Dmg Blockchain
Ecolomondo Corp
First Trust Indxx Medical Devices ETF
Gmv Minerals Inc New
Liberty TripAdvisor Holdings, Inc. - Series B Common Stock
OSI Systems, Inc. - Common Stock
Predictiv Ai Inc
Radius Gold Inc
SciPlay Corporation - Class A Common Stock
Sidney Resources Corp
Toshiba Corp
Tungsten Mng NL
VanEck Space ETF
Velodyne Lidar, Inc. - Common Stock
West Pharmaceutical Services, Inc. Common Stock
XCHG Limited - ADS
Yukon Metals Corp
abrdn Physical Platinum Shares ETF
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MaxCyte, Inc. - Common Stock (NQ:MXCT)

1.300 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,010,052
Open 1.320
Bid (Size) 1.280 (200)
Ask (Size) 1.290 (200)
Prev. Close 1.300
Today's Range 1.280 - 1.320
52wk Range 0.6434 - 1.805
Shares Outstanding 105,482,558
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These stocks have an unusual volume in today's session ↗
October 15, 2026
Via Chartmill
Top movers analysis in the middle of the day on 2026-10-14: top gainers and losers in today's session. ↗
October 14, 2026
Via Chartmill

Performance

52-Week Range 28.0% below 52-week high
1.300
0.6452W Low 1.8052W High
1 Week 2.3% below 1-week high
0.941W Low 1.331W High

MaxCyte, Inc. - Common Stock (MXCT) traded between $0.64 and $1.80 over the past 52 weeks and last traded at $1.30, 28.0% below its 52-week high. Over the past week it ranged between $0.94 and $1.33.

Past 12 Months
+30.7%
+8.8%
+11.1%
+51.2%
-16.1%
-19.3%
1W +$0.31
1M +$0.10
3M +$0.13
6M +$0.44
YTD -$0.25
1Y -$0.31

MXCT was -19.3% over the past year, +51.2% over six months, -16.1% year to date, +30.7% in the last week.

12 Months vs Market
MXCT
-19.3%
DIA
+12.4%
SPY
+14.9%
QQQ
+17.5%
IWM
+11.1%

Over the past 12 months MXCT returned -19.3% versus DIA (Dow) +12.4%, SPY (S&P 500) +14.9%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 1.22× 3-mo avg
Today 1,010,052 3-mo avg 826.9K
1W
3.6M
1M
1.1M
3M
826.9K
6M
1.0M
YTD
1.0M
1Y
1.0M

MXCT most recently traded 1,010,052 shares against a 3-month average daily volume of 826.9K.

More News

Read More
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
October 14, 2026
Via Chartmill
News headline image
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
October 14, 2026
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte (NASDAQ:MXCT) Q1 2026 Results Beat Estimates, Stock Rises on Buyback ↗
May 12, 2026
Via Chartmill
MaxCyte Inc (NASDAQ:MXCT) Reports Q4 2025 Revenue Miss and Cautious 2026 Outlook ↗
March 24, 2026
Via Chartmill
News headline image
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
September 23, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte (MXCT) Q2 2026 Earnings Call Transcript ↗
August 19, 2026
Via The Motley Fool
Topics Earnings
News headline image
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
August 19, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Q2 Earnings Call Highlights ↗
August 12, 2026
Via MarketBeat
Topics Earnings
News headline image
MaxCyte Reports Second Quarter 2026 Financial Results
August 12, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
July 21, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
July 15, 2026
From MaxCyte, Inc
Via GlobeNewswire
There are notable gap-ups and gap-downs in today's session. ↗
May 13, 2026
Via Chartmill
News headline image
MaxCyte Q1 Earnings Call Highlights ↗
May 12, 2026
Via MarketBeat
Topics Earnings
News headline image
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
May 12, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
April 29, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript ↗
March 24, 2026
Via The Motley Fool
Topics Earnings
News headline image
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
March 24, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
March 23, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
February 24, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
February 23, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
January 12, 2026
From MaxCyte, Inc
Via GlobeNewswire

Frequently Asked Questions

Is MaxCyte, Inc. - Common Stock publicly traded?
Yes, MaxCyte, Inc. - Common Stock is publicly traded.
What exchange does MaxCyte, Inc. - Common Stock trade on?
MaxCyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MaxCyte, Inc. - Common Stock?
The ticker symbol for MaxCyte, Inc. - Common Stock is MXCT on the Nasdaq Stock Market
What is the current price of MaxCyte, Inc. - Common Stock?
The current price of MaxCyte, Inc. - Common Stock is 1.300
When was MaxCyte, Inc. - Common Stock last traded?
The last trade of MaxCyte, Inc. - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of MaxCyte, Inc. - Common Stock?
The market capitalization of MaxCyte, Inc. - Common Stock is 137.13M
How many shares of MaxCyte, Inc. - Common Stock are outstanding?
MaxCyte, Inc. - Common Stock has 137M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap